PSVT, Supraventricular Arrhythmia, Supraventricular Tachycardia, Supraventricular Tachycardias, SVT
Conditions
Keywords
Supraventricular Tachycardia, Cardiac Arrhythmias, Cardiovascular Diseases, SVT, Single syringe, Single-syringe
Brief summary
The purpose of the study is to compare the effectiveness of two different methods of administering adenosine for the treatment of stable supraventricular tachycardia (SVT).
Detailed description
The American Heart Association 2015 guidelines recommend adenosine for non-hypotensive patients with regular narrow complex SVT. Adenosine is usually given as a rapid intravenous bolus of 6mg over 1-2 seconds, followed by a 20ml saline flush. If the first dose does not result in the termination of SVT to normal sinus rhythm (NSR) within 1-2 minutes, a repeat dose of 12mg can be given, and the dose may be repeated one more time, if necessary, for a total of three doses. The double-syringe technique (DST) is the standard method for administering adenosine. However, recent studies suggest that the single-syringe technique (SST) may be simpler and potentially beneficial. This technique injects adenosine and saline simultaneously at the same time instead of two separate injections. The study aims to determine if the SST method is non-inferior to the DST method.
Interventions
DRUGSingle-syringe Adenosine
Simplified method, containing both 6 mg of adenosine and 18 mL NS. If SVT termination failed: Second dose of adenosine with SS containing both 12 mg of adenosine and 18 mL NS. A total of three doses could be provided to each patient
DRUGDouble Syringe Adenosine
One Syringe containing 6 mg of adenosine + one syringe containing 20 mL NS aided with a stopcock. If SVT termination failed: Second dose of adenosine (12 mg) + one syringe containing 20 mL NS. A total of three doses could be provided to each
Sponsors
Hormozgan University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 to 80 years * Presentation to the emergency department with narrow-QRS tachyarrhythmia * Heart rate ≥150 beats/min * No visible P wave or presence of retrograde P wave on ECG * Not responsive to Valsalva maneuvers lasting 15 to 30 seconds * Requiring adenosine administration
Exclusion criteria
* Wide-QRS tachycardia or irregular R-R interval on ECG * Known allergy or contraindication to adenosine * Recent ingestion of dipyridamole, carbamazepine, or theophylline * Caffeine ingestion within the previous 2 hours
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| First-dose successful termination of PSVT | Within 2 minutes after administration of the first dose of adenosine. | Proportion of participants with conversion from paroxysmal supraventricular tachycardia to sinus rhythm after the first dose of adenosine. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total administered dose of adenosine. | From administration of the first dose until successful termination of PSVT or up to 10 minutes, whichever occurs first. | Total cumulative dose of adenosine (mg) administered to achieve termination of PSVT. |
Countries
Iran
Outcome results
None listed